Literature DB >> 21080246

Management of refractory ascites and hepatorenal syndrome.

Amy N Sussman1, Thomas D Boyer.   

Abstract

One of the most common manifestations of the development of portal hypertension in the patient with cirrhosis is the appearance of ascites. Once ascites develops, the prognosis worsens and the patient becomes susceptible to complications such as bacterial peritonitis, hepatic hydrothorax, hyponatremia, and complications of diuretic therapy. As the liver disease progresses, the ascites becomes more difficult to treat and many patients develop renal failure. Most patients can be managed by diuretics which, when used correctly, will control the ascites. Spontaneous bacterial peritonitis can be treated effectively, but portends a worse prognosis. Once the ascites becomes refractory to diuretics, liver transplantation is the best option, although use of transjugular intrahepatic portosystemic shunts will control the ascites in many patients. Lastly, the development of hepatorenal syndrome indicates the patient's liver disease is advanced, and transplantation again is the best option. However, use of vasoconstrictors may improve renal function in some patients, helping in their management while they await a liver transplant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21080246     DOI: 10.1007/s11894-010-0156-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  50 in total

Review 1.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

Review 2.  Hepatorenal syndrome: pathophysiology and management.

Authors:  Hani M Wadei; Martin L Mai; Nasimul Ahsan; Thomas A Gonwa
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

Review 3.  Hepatorenal syndrome.

Authors:  R Bataller; P Ginès; M Guevara; V Arroyo
Journal:  Semin Liver Dis       Date:  1997       Impact factor: 6.115

4.  MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.

Authors:  Carlo Alessandria; Osman Ozdogan; Mónica Guevara; Tea Restuccia; Wladimiro Jiménez; Vicente Arroyo; Juan Rodés; Pere Ginès
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 5.  Terlipressin for hepatorenal syndrome.

Authors:  L L Gluud; M S Kjaer; E Christensen
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

6.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.

Authors:  Satheesh Nair; Sumita Verma; Paul J Thuluvath
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

7.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

8.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

Authors:  B Bernard; J D Grangé; E N Khac; X Amiot; P Opolon; T Poynard
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

9.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

10.  Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better?

Authors:  Jillian MacAulay; Kara Thompson; Bryce A Kiberd; David C Barnes; Kevork M Peltekian
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

View more
  4 in total

Review 1.  Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation.

Authors:  Srinivasan Dasarathy
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

2.  Effect of nitric oxide pathway regulation on water/sodium balance and renal function in a rodent model of acute liver and renal failure.

Authors:  Marek Saracyn; Tomasz Ząbkowski; Robert Zdanowski; Marek Brytan; Janusz Patera; Zbigniew Nowak; Grzegorz Kade; Zofia Wańkowicz
Journal:  Med Sci Monit       Date:  2014-09-27

3.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

4.  Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome.

Authors:  Marek Saracyn; Janusz Patera; Janusz Kocik; Marek Brytan; Robert Zdanowski; Arkadiusz Lubas; Wojciech Kozłowski; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.